Phase 2 × Completed × Neuroectodermal Tumors, Primitive, Peripheral × Clear all Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
20 enrolled 12 charts
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
18 enrolled 12 charts
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
4 enrolled 12 charts
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
6 enrolled 12 charts
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Phase 2 Completed
23 enrolled 11 charts
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase 2 Completed
78 enrolled 11 charts
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Phase 2 Completed
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Phase 2 Completed
108 enrolled 14 charts
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 2 Completed
118 enrolled 24 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Phase 2 Completed
50 enrolled 18 charts
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Phase 2 Completed
113 enrolled 13 charts
High-dose ICE With Amifostine
Phase 2 Completed
24 enrolled
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
Phase 2 Completed
56 enrolled 5 charts
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Phase 2 Completed
53 enrolled 6 charts
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase 2 Completed
22 enrolled 6 charts
Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Phase 2 Completed
10 enrolled 7 charts
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
Phase 2 Completed
100 enrolled
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase 2 Completed
120 enrolled
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Phase 2 Completed
10 enrolled 9 charts
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Phase 2 Completed
7 enrolled 6 charts
Vinorelbine in Treating Children With Recurrent or Refractory Cancers
Phase 2 Completed
50 enrolled
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
Phase 2 Completed
15 enrolled 7 charts
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
Phase 2 Completed
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
Phase 2 Completed
35 enrolled
Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma
Phase 2 Completed
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
Phase 2 Completed
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
Irinotecan in Treating Children With Refractory Solid Tumors
Phase 2 Completed
181 enrolled
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
Phase 2 Completed
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Phase 2 Completed
180 enrolled
Docetaxel in Treating Children With Recurrent Solid Tumors
Phase 2 Completed
20 enrolled
Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas
Phase 2 Completed
125 enrolled
Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
Phase 2 Completed
130 enrolled
Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor
Phase 2 Completed
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Phase 2 Completed
54 enrolled 8 charts